comparemela.com

Latest Breaking News On - Scalp investigator global assessment - Page 1 : comparemela.com

Roflumilast Foam Effective for Scalp, Body Psoriasis in Phase 3 Trial

A phase 3 trial evaluating roflumilast foam in patients with scalp and body psoriasis met its coprimary and all secondary endpoints.

Drug administrationScalp investigator global assessmentBody investigator global assessmentNew drug application

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0 3% in Scalp and Body Psoriasis

Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment Success compared to. | September 26, 2022

United statesEric mcintyreAmanda sheldonExchange commissionHead of corporate communicationsGlobenewswire incArcutis biotherapeutics incScalp investigator global assessmentBody investigator global assessmentRial employingArcutis biotherapeuticsNc stock exchangePress releaseOmpared arqt us03969k1088

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0 3% in Scalp and Body Psoriasis

26.09.2022 - Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicleAt . Seite 1

United statesArcutis biotherapeutics incScalp investigator global assessmentBody investigator global assessmentScalp itch numeric rating scaleWorst itch

vimarsana © 2020. All Rights Reserved.